about
Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndromeRadiation dose effect in locally advanced non-small cell lung cancerRadiation dose-fractionation effects in spinal cord: comparison of animal and human dataPulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancerContouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study.Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariatesChanges in functional lung regions during the course of radiation therapy and their potential impact on lung dosimetry for non-small cell lung cancerNondosimetric risk factors for radiation-induced lung toxicity.How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer.Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer.Genetic variations in TGFβ1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancerPros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer.Pattern of failure after high-dose thoracic radiation for non-small cell lung cancer: the University of Michigan experience.Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.Imaging during radiation therapy captures abrupt and dramatic changes.ACR appropriateness Criteria® early-stage non-small-cell lung cancer.Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.Personalized Radiation Therapy (PRT) for Lung Cancer.Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis.Unraveling biophysical interactions of radiation pneumonitis in non-small-cell lung cancer via Bayesian network analysis.Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what?Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.Early Assessment of Treatment Responses During Radiation Therapy for Lung Cancer Using Quantitative Analysis of Daily Computed Tomography.Rebuttal from Prof. Kong and Dr. Rabatic.Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy.Ensuring sample quality for blood biomarker studies in clinical trials: a multicenter international study for plasma and serum sample preparation.Endoscopic Approach to Remove Intra-extracranial Tumors in Various Skull Base Regions: 10-year Experience of a Single Center.Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer.Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer.Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer.Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.A MLC-based inversely optimized 3D spatially fractionated grid radiotherapy technique.Plasma Levels of IL-8 and TGF-β1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study.A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer.Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer
P50
Q26749415-6BC7FF71-9C37-419B-BAEC-402F559074DFQ26823043-16FD35AC-4359-479D-BAB6-BC8A3CB1089FQ30993358-705E183D-4E25-42A2-8705-FCFBF295F179Q34937327-51CA28B3-878D-4BF3-8913-03CDFC0B08E4Q35164466-1E328561-4134-458E-B833-80DF23B4A063Q35199176-FFEBDC67-C391-494D-B407-88468DD41948Q35455018-BCB76D47-30DE-4D48-96D9-9635861AF157Q35456001-3006B298-536D-4A31-9F3D-9C655E183A01Q35900753-FE2963D6-9C94-484C-9805-B0C3C3A9AF1DQ36024114-4FD83115-7089-4A34-90B6-E37AD08EC536Q36433810-90A96D40-0CE5-4BFF-8526-6ECE039934FFQ36821519-3F340FBC-ABE3-4BCD-9B4A-0CAEABB431F2Q36874790-17D997E5-781E-46EC-9C67-AB628D10AC55Q37600525-6DE59AD8-13E5-4C21-8DB6-A2053C858A4FQ37600559-D17ABA56-2947-47FB-B510-E982CA01B9A6Q37658261-C0A31BAD-6F1D-4A95-B08F-EA927C900865Q38245475-309951AC-0022-46D3-8B9C-3098E3CCAC7FQ38376135-68ED37F8-F102-4348-97E5-B65B68BF3744Q38679314-A10198BC-ABE3-4B62-A8EE-957B9E293599Q38914996-0A724106-0382-43DE-A977-AC97F7A6CE27Q38942182-330E6473-C5EA-41E0-9DF6-9E4D2118D734Q38962875-514F2F59-CF33-43F9-8384-C3D0BA3B0E1AQ39015830-8F24A3F3-5932-4E05-AEEE-C22C2880922CQ40219054-87E9CCCF-685B-46C5-9573-531EAC949488Q41081446-E1BA8E1D-6E88-4188-A69E-95F702DF51E4Q42362026-E4EAD966-C303-450A-8378-94D7EB97DE91Q47097808-F487D033-8B2F-416D-ACFE-E730134D0C78Q47119326-1E91DDD2-D588-4B53-B70D-EC6244B9A11CQ47138202-F4C10E9C-FB65-43EB-B530-49344C4F734DQ47428325-CD14350C-1674-422D-9661-E1F2E9A48C54Q47445024-EC120E59-5222-4BD2-9FFA-634E73974969Q47651774-60DE0C68-A634-44CB-B656-97A9A4D38FBDQ47821832-BB5BBD9E-44A4-4522-AACF-B8E4F456CBBBQ47860971-29F80A92-8395-4461-919F-9E0717700998Q50103704-680FB8DC-EDF4-40A0-91DB-B04034213E0FQ50795251-4B325C45-6522-47B4-9E1A-40D3817BB888Q50945544-9390E187-1F87-4DCB-A6F8-00B164D54F82Q50959320-345697FB-8751-4273-9014-10DFA97AB395Q55279852-F70F1C39-14F6-4CD3-B3F5-3980C43EF19DQ58594704-634D06C0-1BE5-4004-B11D-AF3AF3CE7C19
P50
description
investigador
@es
researcher
@en
name
Feng-Ming Spring Kong
@en
type
label
Feng-Ming Spring Kong
@en
prefLabel
Feng-Ming Spring Kong
@en
P31
P496
0000-0003-2652-098X